SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ermias Diro, Lutgarde Lynen, Berhane Gebregziabiher, Abraham Assefa, Wubishet Lakew, Zewdu Belew, Asrat Hailu, Marleen Boelaert, Johan Griensven, Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia, Tropical Medicine & International Health, 2015, 20, 1
  2. 2
    Niven A. Salih, Johan Griensven, François Chappuis, Annick Antierens, Ann Mumina, Omar Hammam, Philippa Boulle, Emilie Alirol, Mubarak Alnour, Mousab S. Elhag, Marcel Manzi, Walter Kizito, Rony Zachariah, Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?, Tropical Medicine & International Health, 2014, 19, 2
  3. 3
    Marleen Boelaert, Shyam Sundar, Manson's Tropical Infectious Diseases, 2014,

    CrossRef

  4. 4
    Fernando Cobo, Imported Infectious Diseases, 2014,

    CrossRef

  5. 5
    Sarfaraz Ahmad Ejazi, Nahid Ali, Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects, Expert Review of Anti-infective Therapy, 2013, 11, 1, 79

    CrossRef

  6. 6
    Begoña Monge-Maillo, Rogelio López-Vélez, Therapeutic Options for Visceral Leishmaniasis, Drugs, 2013, 73, 17, 1863

    CrossRef

  7. 7
    Saied Soflaei, Abdolhossein Dalimi, Fatemeh Ghaffarifar, Mojtaba Shakibaie, Ahmad Reza Shahverdi, Mohsen Shafiepour, In VitroAntiparasitic and Apoptotic Effects of Antimony Sulfide Nanoparticles onLeishmania infantum, Journal of Parasitology Research, 2012, 2012, 1

    CrossRef

  8. 8
    K. Ritmeijer, R. ter Horst, S. Chane, E. M. Aderie, T. Piening, S. M. Collin, R. N. Davidson, Limited Effectiveness of High-Dose Liposomal Amphotericin B (AmBisome) for Treatment of Visceral Leishmaniasis in an Ethiopian Population With High HIV Prevalence, Clinical Infectious Diseases, 2011, 53, 12, e152

    CrossRef

  9. 9
    S. Rijal, S. Bhandari, S. Koirala, R. Singh, B. Khanal, L. Loutan, J.C. Dujardin, M. Boelaert, F. Chappuis, Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, 104, 3, 225

    CrossRef

  10. 10
    Smriti Mondal, Pradyot Bhattacharya, Nahid Ali, Current diagnosis and treatment of visceral leishmaniasis, Expert Review of Anti-infective Therapy, 2010, 8, 8, 919

    CrossRef

  11. 11
    Workagegnehu Hailu, Teklu Weldegebreal, Zewdu Hurissa, Hailemariam Tafes, Raymond Omollo, Sisay Yifru, Manica Balasegaram, Asrat Hailu, Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, 104, 11, 706

    CrossRef

  12. 12
    M. Boelaert, F. Meheus, J. Robays, P. Lutumba, Socio–economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis, Annals of Tropical Medicine & Parasitology, 2010, 104, 7, 535

    CrossRef

  13. 13
    ALAN J. MAGILL, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  14. 14
    Bhuwan B. Mishra, Raju R. Kale, Rakesh K. Singh, Vinod K. Tiwari, Alkaloids: Future prospective to combat leishmaniasis, Fitoterapia, 2009, 80, 2, 81

    CrossRef

  15. 15
    Yolanda Mueller, Dawson B. Mbulamberi, Peter Odermatt, Axel Hoffmann, Louis Loutan, François Chappuis, Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda, Tropical Medicine & International Health, 2009, 14, 8
  16. 16
    Y. Mueller, A. Nguimfack, P. Cavailler, S. Couffignal, J. B. Rwakimari, L. Loutan, F. Chappuis, Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda, Annals of Tropical Medicine & Parasitology, 2008, 102, 1, 11

    CrossRef

  17. 17
    V. Vanlerberghe, G. Diap, P. J. Guerin, F. Meheus, S. Gerstl, P. Van der Stuyft, M. Boelaert, Drug policy for visceral leishmaniasis: a cost-effectiveness analysis, Politique des médicaments contre la leishmaniose viscérale: une analyse de coût efficacité, Política de medicamentos para la Leishmaniasis Visceral: análisis de costo-efectividad, Tropical Medicine & International Health, 2007, 12, 2
  18. 18
    François Chappuis, Shyam Sundar, Asrat Hailu, Hashim Ghalib, Suman Rijal, Rosanna W. Peeling, Jorge Alvar, Marleen Boelaert, Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?, Nature Reviews Microbiology, 2007, 5, 11, S7

    CrossRef

  19. 19
    S. Gerstl, R. Amsalu, K. Ritmeijer, Accessibility of diagnostic and treatment centres for visceral leishmaniasis in Gedaref State, northern Sudan, Accessibilité au diagnostic et au traitement de la leishmaniose viscérale dans l’état de Gedaref au nord du Soudan, Accesibilidad a centros de diagnóstico y tratamiento de leishmaniasis visceral en el estado de Gedaref, norte de Sudan, Tropical Medicine & International Health, 2006, 11, 2
  20. 20
    Laura Vásquez, José V. Scorza Dagert, José V. Scorza, Nelson Vicuña-Fernández, Yaneira Petit de Peña, Sabrina López, Herminia Bendezú, Elina Rojas, Libia Vásquez, Belén Pérez, Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers, Current Therapeutic Research, 2006, 67, 3, 193

    CrossRef

  21. 21
    Margriet den Boer, Robert N Davidson, Treatment options for visceral leishmaniasis, Expert Review of Anti-infective Therapy, 2006, 4, 2, 187

    CrossRef

  22. 22
    Simon M. Collin, Paul G. Coleman, Koert Ritmeijer, Robert N. Davidson, Unseen Kala-azar deaths in south Sudan (1999–2002), Communication brève: Décès dues au kala-azar et passés inaperçus dans le sud du Soudan (1999–2002), Comunicación corta: Muertes no detectadas por kala-azar en el sur de Sudan (1999–2002), Tropical Medicine & International Health, 2006, 11, 4
  23. 23
    Henry W Murray, Jonathan D Berman, Clive R Davies, Nancy G Saravia, Advances in leishmaniasis, The Lancet, 2005, 366, 9496, 1561

    CrossRef

  24. 24
    Jonathan Berman, Recent developments in Leishmaniasis: Epidemiology, diagnosis, and treatment, Current Infectious Disease Reports, 2005, 7, 1, 33

    CrossRef

  25. 25
    Shyam Sundar, Madhukar Rai, Treatment of visceral leishmaniasis, Expert Opinion on Pharmacotherapy, 2005, 6, 16, 2821

    CrossRef

  26. 26
    Piero L Olliaro, Philippe J Guerin, Sibylle Gerstl, Astrid Aga Haaskjold, John-Arne Rottingen, Shyam Sundar, Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004, The Lancet Infectious Diseases, 2005, 5, 12, 763

    CrossRef

  27. 27
    Jonathan Berman, Current treatment approaches to leishmaniasis, Current Opinion in Infectious Diseases, 2003, 16, 5, 397

    CrossRef

  28. 28
    P Minodier, S Robert, K Retornaz, J.M Garnier, Leishmaniose viscérale infantile : nouvelles thérapeutiques, Archives de Pédiatrie, 2003, 10, s550

    CrossRef

  29. 29
    K. Ritmeijer, R.N. Davidson, Médecins Sans Frontières interventions against kala-azar in the Sudan, 1989–2003, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 6, 609

    CrossRef

  30. 30
    S. Rijal, F. Chappuis, R. Singh, M. Boelaert, L. Loutan, S. Koirala, Sodium stibogluconate cardiotoxicity and safety of generics, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 5, 597

    CrossRef

  31. 31
    S. Rijal, F. Chappuis, R. Singh, P.A. Bovier, P. Acharya, B.M.S. Karki, M.L. Das, P. Desjeux, L. Loutan, S. Koirala, Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 3, 350

    CrossRef

  32. 32
    Shyam Sundar, Madhukar Rai, Advances in the treatment of leishmaniasis, Current Opinion in Infectious Diseases, 2002, 15, 6, 593

    CrossRef

  33. 33
    M. Boelaert, D. Le Ray, P. Van der Stuyft, How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis, Tropical Medicine & International Health, 2002, 7, 11
  34. 34
    Eric Rosenthal, Pierre Marty, Treatment of visceral leishmaniasis: a review of current treatment practices, Expert Opinion on Pharmacotherapy, 2002, 3, 8, 1101

    CrossRef

  35. 35
    Philippe J Guerin, Piero Olliaro, Shyam Sundar, Marleen Boelaert, Simon L Croft, Philippe Desjeux, Monique K Wasunna, Anthony DM Bryceson, Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda, The Lancet Infectious Diseases, 2002, 2, 8, 494

    CrossRef

  36. 36
    E.E. Zijlstra, A.M. El-Hassan, 3. Visceral leishmaniasis, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, S27

    CrossRef

  37. 37
    K. Ritmeijer, H. Veeken, Y. Melaku, G. Leal, R. Amsalu, J. Seaman, R.N. Davidson, Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 6, 668

    CrossRef

  38. 38
    Hans Veeken, Bernard Pécoul, Editorial: Drugs for ‘neglected diseases’: a bitter pill, Tropical Medicine & International Health, 2000, 5, 5
  39. 39
    Omran F. Osman, Piet A. Kager, Linda Oskam, Leishmaniasis in the Sudan: a literature review with emphasis on clinical aspects, Tropical Medicine & International Health, 2000, 5, 8